ELABELA及其片段对急性肾损伤的保护作用
本研究探讨了ELABELA(ELA)成熟肽(ELA32)及其弗林蛋白酶切割的11残基片段(ELA11)对肾缺血再灌注(I/R)损伤的保护作用。在体外,ELA32和ELA11可抑制缺氧再灌注(H/R)损伤的肾小管细胞及阿霉素处理细胞中的DNA损伤反应、凋亡和炎症;在体内,给予小鼠ELA32或ELA11(而非N端半胱氨酸突变为丙氨酸的ELA11突变体AE11C)可抑制I/R损伤诱导的肾纤维化、炎症、凋亡和DNA损伤反应,并显著减轻肾小管病变和肾功能障碍。结果表明ELA32和ELA11可能成为治疗AKI的候选药物。
要点
- ELA32和ELA11在体外抑制H/R损伤肾小管细胞的DNA损伤反应、凋亡和炎症。
- ELA32或ELA11而非突变体AE11C可减轻小鼠I/R损伤诱导的肾纤维化、炎症和肾功能障碍。
- ELA32和ELA11可能是治疗急性肾损伤的候选药物。
核心结论
- ELA32和ELA11对肾缺血再灌注损伤具有保护作用,可能成为治疗AKI的候选药物。
研究设计与样本
- 体外实验:对缺氧再灌注(H/R)损伤或阿霉素处理的肾小管细胞给予ELA32或ELA11。
- 体内实验:对缺血再灌注(I/R)损伤小鼠给予ELA32、ELA11或ELA11突变体AE11C。
主要发现
- 体外:ELA32和ELA11显著抑制H/R损伤肾小管细胞的DNA损伤反应、凋亡和炎症,并抑制阿霉素诱导的DNA损伤反应。
- 体外:过表达ELA32或ELA11显著抑制H/R诱导的细胞死亡、DNA损伤反应和炎症。
- 体内:ELA32或ELA11(而非AE11C)抑制I/R损伤诱导的肾纤维化、炎症、凋亡和DNA损伤反应,并显著减轻肾小管病变和肾功能障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renal ischemia-reperfusion (I/R) injury is the most common cause of AKI, which associates with high mortality and has no effective therapy. ELABELA (ELA) is a newly identified 32-residue hormone peptide highly expressed in adult kidney. To investigate whether ELA has protective effects on renal I/R injury, we administered the mature peptide (ELA32) or the 11-residue furin-cleaved fragment (ELA11) to hypoxia-reperfusion (H/R)-injured or adriamycin-treated renal tubular cells in vitro ELA32 and ELA11 significantly inhibited the elevation of the DNA damage response, apoptosis, and inflammation in H/R-injured renal tubular cells and suppressed adriamycin-induced DNA damage response. Similarly, overexpression of ELA32 or ELA11 significantly inhibited H/R-induced cell death, DNA damage response, and inflammation. Notably, treatment of mice with ELA32 or ELA11 but not an ELA11 mutant with a cysteine to alanine substitution at the N terminus (AE11C) inhibited I/R injury-induced renal fibrosis, inflammation, apoptosis, and the DNA damage response and markedly reduced the renal tubular lesions and renal dysfunction. Together, our results suggest that ELA32 and ELA11 may be therapeutic candidates for treating AKI.
引用
- Chen H, Wang L, Wang W, et al. ELABELA and an ELABELA Fragment Protect against AKI. J Am Soc Nephrol. 2017. PMID: 28583915. doi:10.1681/ASN.2016111210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。